Soleus Capital Management, L.P. Protagonist Therapeutics, Inc Transaction History

Soleus Capital Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$21.79 - $32.15 $1.06 Million - $1.56 Million	-48,500 Reduced 58.43%	34,500 $998,000
Q4 2023 Feb 14, 2024	BUY	$14.05 - $23.44 $1.17 Million - $1.95 Million	83,000 New	83,000 $1.9 Million
Q2 2023 Aug 14, 2023	BUY	$18.02 - $29.36 $717,196 - $1.17 Million	39,800 New	39,800 $1.1 Million
Q4 2022 Feb 14, 2023	BUY	$7.36 - $11.17 $1.74 Million - $2.64 Million	236,000 New	236,000 $2.57 Million

212

59.1M

19K

107K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.25B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Soleus Capital Management, L.P. with notifications on news.